Top Markets
Coin of the day
Medivir AB (publ) Medivir AB (publ)

Medivir AB (publ)

MVIR-B
Classement en actions #29656
Medivir AB (publ) is a pharmaceutical company established in 1987 and... Medivir AB (publ) is a pharmaceutical company established in 1987 and headquartered in Huddinge, Sweden. It is dedicated to the research, development, and global commercialization of medicines, with a primary focus on oncology. The company currently markets Zoviduo (formerly Xerclear) for the treatment of labial herpes. Its robust development pipeline includes Remetinostat, targeting MF cutaneous T-cell lymphoma and basal cell carcinoma; MIV-818, aimed at liver cancer; and MIV-711, being advanced for osteoarthritis. Additionally, Medivir is progressing Birinapant and IGM-8444 for various solid tumor indications. Collaborative efforts are also key to its strategy, including a research partnership with SciLifeLab's Drug Discovery and Development Platform to discover antivirals for SARS CoV-2, alongside licensing agreements with Tango Therapeutics for a preclinical research program and with Ubiquigent Limited for the USP7 preclinical research program.
Prix de l'action
$0.68377137
Dernière synchronisation: 2023-05-23
Capitalisation boursière
$20.23M
Changement (1 jour)
-0.60%
Changement (1 an)
0.00%
Pays
SE
Échange Medivir AB (publ) (MVIR-B)

Catégorie

EPS pour Medivir AB (publ) (MVIR-B)
EPS au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Medivir AB (publ), l’EPS actuel de la société (TTM) est de 0. À la fin de 2026, la société avait un EPS de 0 égal à celui de 2026, qui était de 0.
Historique de l'EPS de Medivir AB (publ) de 2026 à 2026
EPS à la fin de chaque année
Année EPS Changez
Pas assez de données pour les dates fournies.
EPS pour des entreprises ou concurrents similaires
Entreprise EPS Différence d’EPS Pays
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$2.98 -
AU
- -
CH